Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, induces apoptosis in multiple myeloma cells in an IκBα-independent manner
Authors:
Open Access
- 1 July 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 4 (7) , 1114-1120
Abstract
Nuclear factor-κB (NF-κB) is constitutively activated in multiple myeloma cells. Several proteasome inhibitors have been shown to be effective against multiple myeloma and may act by inhibiting degradation of IκBα. Here, we examined the biological effects of a new type of NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), which is reported to directly inhibit the cytoplasm-to-nucleus translocation of NF-κB. A multiple myeloma cell line, 12PE, which is defective for IκBα protein, was utilized to determine if IκBα is concerned with the action of DHMEQ. Meanwhile, U266 was used as a multiple myeloma cell line with normal IκBα. A proteasome inhibitor, gliotoxin, which is an inhibitor of degradation of phosphorylated IκBα, failed to inhibit translocation of NF-κB in 12PE. In contrast, DHMEQ equally inhibited translocation of NF-κB to the nucleus and induced apoptosis to both multiple myeloma cell lines, suggesting that apoptosis resulting from DHMEQ is IκBα independent. DHMEQ also induced apoptosis in freshly isolated multiple myeloma cells. After DHMEQ treatment, cleavage of caspase-3 and down-regulation of cyclin D1 were observed in both cell lines. In addition, administration of DHMEQ resulted in a significant reduction in tumor volume in a plasmacytoma mice model compared with control mice. Our results show that DHMEQ could potentially be a new type of molecular target agent for multiple myeloma.Keywords
This publication has 34 references indexed in Scilit:
- Nuclear factor–κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosisBlood, 2004
- Inactivating I kappa B epsilon mutations in Hodgkin/Reed–Sternberg cellsThe Journal of Pathology, 2003
- Cyclin D1 Splice VariantsJournal of Biological Chemistry, 2003
- Identification of polymorphisms of the IκBα gene associated with an increased risk of multiple myelomaCancer Genetics and Cytogenetics, 2002
- Inhibition of Tumor Necrosis Factor-α-induced Nuclear Translocation and Activation of NF-κB by DehydroxymethylepoxyquinomicinJournal of Biological Chemistry, 2002
- Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin CBioorganic & Medicinal Chemistry Letters, 2000
- The Rel/NF-κB signal transduction pathway: introductionOncogene, 1999
- Activators and target genes of Rel/NF-κB transcription factorsOncogene, 1999
- The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappa B that blocks TNFalpha -induced apoptosisGenes & Development, 1999
- Two human myeloma cell lines, amylase‐producing KMS‐12‐PE and amylase‐non‐producing KMS‐12‐BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32)British Journal of Haematology, 1989